Reducing Chronic Pain Following Cesarean Delivery
A Pilot Feasibility Study of an Intervention to Reduce Chronic Pain Following Cesarean Delivery
This pilot study will evaluate the feasibility and acceptability of delivering Empowered Relief (ER), a single-session pain relief skills class, to postpartum women with ongoing pain and/or pain interference following cesarean delivery. Participants will receive ER in addition to standard postpartum care and will be followed through 12 weeks postpartum.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
California
-
Palo Alto, California, Estados Unidos, 94304
- Recrutamento
- Stanford Medicine Children's Health - Specialty Services, Welch Road
-
Investigador principal:
- Pervez Sultan, MD
-
Contato:
- Pervez Sultan, MD
- Número de telefone: (669) 800 9929
- E-mail: psultan@stanford.edu
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Complete informed consent.
- Age 18 years or above.
- Postpartum woman who delivered by cesarean within the Stanford Healthcare system.
- Viable birth (singleton or multiple gestation).
- All maternal demographics and complications are eligible: parity, medical conditions (e.g., pre-eclampsia, gestational diabetes), and post-surgical complications (e.g., hysterectomy, ICU admission, extended hospital stay).
- All neonatal complications are eligible (e.g., NICU admission, extended hospital stay)
- Attend the 6-week postpartum clinic visit.
- Any pain intensity (numeric rating scale [NRS] >0/10) and/or pain interference (PROMIS pain interference 8a score >8) at 6 weeks postpartum.
- English fluency, with ability to read and write.
- Ability to adhere to and complete study procedures.
- Access to a smart device if attending ER session via Zoom.
Exclusion Criteria:
- Age under 18 years.
- Cognitive impairment or psychological factors that would preclude comprehension of study material or full participation.
- Unable or unwilling to provide informed consent.
- Chronic pain prior to pregnancy.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Empowered Relief
Participants will receive a single 120-minute Empowered Relief session in addition to standard postpartum care. The session includes pain education and cognitive-behavioral pain management skills, including relaxation, deep breathing, reframing, and development of a personalized plan. Participants will also receive access to a smartphone relaxation resource (Calm Tool app, or a relaxation audio file if the app cannot be downloaded). |
A single 120-minute pain relief skills class delivered by trained, certified instructors via Zoom or in person. The session includes pain education, cognitive behavioral skills including relaxation, deep breathing, and reframing, and completion of a personalized plan. Following the session, participants receive access to the Calm Tool smartphone relaxation app (or a binaural relaxation audio file if the app cannot be downloaded). |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of enrolled patients that complete the Empowered Relief session
Prazo: Within 2 weeks of enrollment
|
The proportion of enrolled patients that complete the single 120-minute Empowered Relief session. |
Within 2 weeks of enrollment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of screened patients who are eligible for the study
Prazo: During screening, at approximately 6 weeks postpartum
|
The proportion of screened patients that meet the study eligibility criteria. |
During screening, at approximately 6 weeks postpartum
|
|
Proportion of eligible patients that consent to study from those approached
Prazo: During screening and enrollment, at approximately 6 weeks postpartum
|
The proportion of eligible patients who provide informed consent and enroll in the study. |
During screening and enrollment, at approximately 6 weeks postpartum
|
|
Proportion of recruited patients who register for the Empowered Relief session
Prazo: Within 1 week of enrollment
|
The proportion of recruited patients who register for the Empowered Relief session. |
Within 1 week of enrollment
|
|
Proportion of recruited patients who attend the Empowered Relief session
Prazo: Within 2 weeks of baseline
|
The proportion of recruited patients who attend an Empowered Relief session. |
Within 2 weeks of baseline
|
|
Treatment Appraisal score
Prazo: Immediately after the Empowered Relief session, up to 2 weeks post-treatment
|
Treatment satisfaction assessed using the 7-item treatment appraisal questionnaire. Range 0-42, higher = greater satisfaction with the intervention |
Immediately after the Empowered Relief session, up to 2 weeks post-treatment
|
|
Qualitative feedback regarding the Empowered Relief intervention
Prazo: Immediately after the Empowered Relief session, up to 2 weeks post-treatment
|
Participant feedback regarding the Empowered Relief intervention, provided through optional free-text responses included in the Treatment Appraisal Questionnaire. |
Immediately after the Empowered Relief session, up to 2 weeks post-treatment
|
|
Participant Treatment Skills Use Scale score
Prazo: Weekly from completion of the Empowered Relief session through 12 weeks postpartum
|
Use of skills learned during the Empowered Relief intervention assessed using the 5-item Participant Treatment Skills Use Scale. Total scores range from 0 to 25, with higher scores indicating greater use of treatment skills. |
Weekly from completion of the Empowered Relief session through 12 weeks postpartum
|
|
Adherence to Study Procedures: completion rate of scheduled surveys
Prazo: From baseline at approximately 6 weeks postpartum through end-of-study at approximately 12 weeks postpartum
|
The percentage of scheduled study surveys completed by enrolled participants. |
From baseline at approximately 6 weeks postpartum through end-of-study at approximately 12 weeks postpartum
|
|
Adherence to study procedures: completion rate of scheduled PEG assessments
Prazo: From baseline at approximately 6 weeks postpartum through end-of-study at approximately 12 weeks postpartum
|
The percentage of scheduled Pain, Enjoyment, General Activity (PEG) assessments completed by enrolled participants. |
From baseline at approximately 6 weeks postpartum through end-of-study at approximately 12 weeks postpartum
|
|
Adherence to study procedures: proportion of participants retained through end-of-study follow-up
Prazo: From baseline at approximately 6 weeks postpartum through end-of-study at approximately 12 weeks postpartum
|
The proportion of enrolled participants who remain in the study through the end-of-study follow-up assessment. |
From baseline at approximately 6 weeks postpartum through end-of-study at approximately 12 weeks postpartum
|
Colaboradores e Investigadores
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 84718
- K24DA053564 (Concessão/Contrato do NIH dos EUA)
- R90HD118650 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .